Research programme: proteostasis regulators - Proteostasis Therapeutics

Drug Profile

Research programme: proteostasis regulators - Proteostasis Therapeutics

Alternative Names: PTI 808; PTI-130; PTI-C1811; PTI-P271

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator Proteostasis Therapeutics
  • Developer Biogen; Cystic Fibrosis Foundation Therapeutics; Harvard Medical School; Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants; Protein folding modulators; Protein modulators; USP14 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis; Neurodegenerative disorders
  • Research Inflammation; Metabolic disorders; Parkinson's disease

Most Recent Events

  • 04 Jul 2017 Proteostasis Therapeutics files an IND application with the FDA in USA for Cystic fibrosis
  • 30 Mar 2017 Proteostasis Therapeutics plans to file an IND application for PTI 808 with the US FDA for Cystic fibrosis
  • 30 Mar 2017 Proteostasis Therapeutics plans a phase I trial for PTI 808 for Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top